Sana Biotechnology (SANA) Total Current Liabilities (2020 - 2026)

Sana Biotechnology has disclosed Total Current Liabilities across 7 years of filings, most recently posting $86.3 million for Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $86.3 million, up 160.18% year-over-year; the trailing twelve-month figure through Mar 2026 was $86.3 million (up 160.18% YoY), and the FY2025 annual result was $78.7 million, up 73.28% from the prior year.
• Total Current Liabilities came in at $86.3 million for Q1 2026 at Sana Biotechnology, up from $78.7 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $114.8 million in Q3 2022 to a low of $33.2 million in Q1 2025.
• The 5-year median for Total Current Liabilities is $66.6 million (2023), against an average of $72.1 million.
• Across the five-year window, Total Current Liabilities surged 166.03% in 2022 and slumped 54.78% in 2024, its largest moves.
• Sana Biotechnology's Total Current Liabilities stood at $111.5 million in 2022, then slumped by 42.17% to $64.5 million in 2023, then retreated by 29.55% to $45.4 million in 2024, then jumped by 73.28% to $78.7 million in 2025, then advanced by 9.58% to $86.3 million in 2026.
• The last three Total Current Liabilities figures came in at $86.3 million (Q1 2026), $78.7 million (Q4 2025), and $35.5 million (Q3 2025), per Business Quant data.